Kevin Tang bought $711K of Boundless Bio (BOLD)
Executed Jun 25, disclosed Jun 29, 4 days later.
Over the 21 trading sessions from the disclosed entry session (Jun 29), the stock returned -3.1% (delay-adjusted); from the execution session (Jun 25), -5.3%. Derived: entry at the session's open, exit at the close 20 sessions later.
Kevin Tang (Director) filed 9 Form 4 reports in the trailing twelve months (9 purchases, 0 sales), most often in Aurinia Pharmaceuticals Inc. (AUPH). Across 8 priced purchase filings, the average 21-session return was +4.8% from execution and +6.8% from disclosure (delay-adjusted; derived). The largest single filing was $12.7M of AUPH (898,400 sh across 5 lots, as filed), executed Feb 27.
Healthcare · Boundless Bio, Inc., a clinical-stage oncology company, develops interrogating extrachromosomal DNA (ecDNA) directed therapies for treating…
More Healthcare filings→ Insider filings, newest first→ View the original filing at www.sec.gov→118,185 sh × $2.34
Exec Oct 16
Filed Oct 20 · 5:49 PM ET BOLDPURCHASE Boundless Bio, Inc. $107K
43,878 sh × $2.43
Exec Jul 14
Filed Jul 16 · 8:10 PM ET BOLDPURCHASE Boundless Bio, Inc. $222K
91,578 sh across 2 lots
Exec Jul 10
Filed Jul 13 · 7:06 PM ET BOLDPURCHASE Boundless Bio, Inc. $178K
71,612 sh × $2.49
Exec Jul 1
Filed Jul 2 · 7:45 PM ET